Condition (MeSH)
Mevalonate Kinase Deficiency
ClinicalTrials.gov lists 6 trials for Mevalonate Kinase Deficiency or a narrower condition beneath it. Novartis Pharmaceuticals has the most among industry and government lead sponsors, with 3.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
6 of the 6 trials are tagged with Mevalonate Kinase Deficiency itself; the rest are tagged with a narrower condition beneath it.
When did Mevalonate Kinase Deficiency trials start? (6)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 2
- Phase 3
- Not applicable
- Observational
Top of scale: 1
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2025 | 1 |
| 2022 | 1 |
| 2014 | 1 |
| 2012 | 1 |
| 2011 | 1 |
| 2005 | 1 |
No forecast is made for this condition: it averages 0.4 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 6 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Mevalonate Kinase Deficiency trials in? (4)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 2 | 1 |
| Phase 3 | 1 |
| Not applicable | 1 |
| Observational | 3 |
How many Mevalonate Kinase Deficiency trials are recruiting? (5)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 1 |
| Completed | 2 |
| Terminated | 1 |
| Withdrawn | 1 |
| Unknown status | 1 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Mevalonate Kinase Deficiency trials? (1)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Novartis Pharmaceuticals | 3 |
Which serious adverse events do Mevalonate Kinase Deficiency trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Abdominal pain | 2 | 1 |
| Arthritis | 2 | 1 |
| Anaemia | 1 | 1 |
| Bone disorder | 1 | 1 |
| Cellulitis | 1 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Mevalonate Kinase Deficiency? (7)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| [Mevalonate kinase deficiency]. | La Revue du praticien | 2023 | Yes |
| Long-term efficacy and safety of canakinumab in patients with mevalonate kinase deficiency: results from the randomised Phase 3 CLUSTER trial. | Rheumatology (Oxford, England) | 2022 | Yes |
| Classification criteria for autoinflammatory recurrent fevers. | Annals of the rheumatic diseases | 2019 | Yes |
| Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes. | The New England journal of medicine | 2018 | Yes |
| Open-Label, Phase II Study to Assess the Efficacy and Safety of Canakinumab Treatment in Active Hyperimmunoglobulinemia D With Periodic Fever Syndrome. | Arthritis & rheumatology (Hoboken, N.J.) | 2017 | Yes |
Showing 5 of 7 publications.
Prevalence (6)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Mevalonate kinase deficiency | Point prevalence | <1 / 1 000 000 | Worldwide | Not stated | Unspecified |
| Mevalonate kinase deficiency | Point prevalence | <1 / 1 000 000 | Worldwide | Not stated | Exact |
| Mevalonate kinase deficiency | Cases families | Worldwide | Not stated | Exact | |
| Mevalonate kinase deficiency | Point prevalence | <1 / 1 000 000 | Worldwide | Not stated | Exact |
| Mevalonate kinase deficiency | Cases families | Worldwide | Not stated | Unspecified |
Showing 5 of 6 prevalence observations.
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Mevalonate kinase deficiency | 309025 | Exact | Orphadata Science knowledge files, Product 1 |
| Mevalonate kinase deficiency | 309025 | Exact | Orphanet Rare Disease Ontology (ORDO) |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: sub-conditions in mesh.
Not computed for conditions with fewer than 10 trials: drugs tested.